Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30862234 | 0.88 | SLC6A2 (0.54) | OPRM1OPRD1ACESLC6A2 | |
| SCHEMBL29575836 | 0.86 | SLC6A2 (0.55) | OPRM1ACESLC6A2 | |
| SCHEMBL29461794 | 0.86 | TACR1 (0.56) | OPRM1 | |
| SCHEMBL31612928 | 0.84 | VHL (0.51) | OPRM1OPRD1ACESLC6A2 | |
| SCHEMBL30637543 | 0.84 | OPRM1 (0.62) | OPRM1OPRD1SLC6A2 | |
| SCHEMBL29794254 | 0.84 | OPRM1 (0.62) | OPRM1OPRD1SLC6A2 | |
| SCHEMBL31267118 | 0.83 | ITGB1 (0.54) | OPRM1OPRD1ACESLC6A2 | |
| SCHEMBL31406961 | 0.83 | OPRM1 (0.62) | OPRM1OPRD1SLC6A2 | |
| SCHEMBL30110409 | 0.83 | OPRM1 (0.49) | OPRM1OPRD1ACESLC6A2 | |
| SCHEMBL31031470 | 0.82 | CAPN1 (0.38) | OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12257323-B2 | Modified wound dressings | CONVATEC TECHNOLOGIES INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240123091-A1 | MODIFIED WOUND DRESSINGS | CONVATEC TECHNOLOGIES, INC. | 2024-04-18 | — | — | US | disclosed |
| US-11865192-B2 | Modified wound dressings | CONVATEC TECHNOLOGIES, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-11807899-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited | 2023-11-07 | — | — | US | disclosed |
| EP-3436012-B1 | MODIFIED WOUND DRESSINGS | CONVATEC TECHNOLOGIES INC (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20220145378-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240123091-A1 | MODIFIED WOUND DRESSINGS | MMP8, CD68, ELANE | OPRM1 3161/4885OPRD1 3705/4885ACE 258/4885 |
| US-11865192-B2 | Modified wound dressings | MMP8, CD68, ELANE | OPRM1 3161/4885OPRD1 3705/4885ACE 258/4885 |
| US-12257323-B2 | Modified wound dressings | MMP8, CD68, ELANE | OPRM1 3161/4885OPRD1 3705/4885ACE 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.